Niagen Bioscience, Inc. — Director's Dealing 2011

Mar 4, 2011

SEC Form 4/A — Form 4/A

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2010-05-20

Reporting Person: BLOCK STEPHEN A (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-05-20	Employee Stock Options (right to buy)	$1.545	A	113750	Acquired	2020-05-20	Common Stock (113750)	Direct
2010-05-20	Employee Stock Options (right to buy)	$1.545	A	113750	Acquired	2020-05-20	Common Stock (113750)	Direct
2010-05-20	Employee Stock Options (right to buy)	$1.545	A	97500	Acquired	2020-05-20	Common Stock (97500)	Direct

Footnotes

F1: Options vest 50% over two years beginning on May 20, 2011.

F2: Options vest 50% over two years beginning on May 20, 2011; provided further that these options are only exercisable based on the percentage of warrants exercised as of such vesting date that were issued under that certain Subscription Agreement, dated as of April 22, 2010, between the Issuer and the subscribers named therein. Specifically, if 25% to 49.9% of such warrants have been exercised, then 25% of of these options are exercisable; if 50% to 74% of such warrants have been exercised, then 50% of these options are exercisable; and if 75% or more of such warrants have been exercised, then 100% of these options are exercisable.

F3: Options vest 1/12 every month for twelve months.